|Mr. Martin J. Duvall||CEO & Director||782.68k||N/A||1962|
|Mr. Thomas E. Darcy||Co-Founder & Director||35k||N/A||1951|
|Dr. Douglas J. Jolly||Co-Founder and Exec. VP of Research & Pharmaceutical Devel.||416.87k||N/A||1948|
|Mr. Mark G. Foletta CPA, CPA||Exec. VP & CFO||540.1k||N/A||1961|
|Dr. Harry E. Gruber||Founder, Adviser & Director||N/A||N/A||1953|
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.
Tocagen Inc.’s ISS governance QualityScore as of 4 October 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 8; Compensation: 9.